# INTEGRATED BIOPHARMA, INC. (INBP) · Edgar & Edgarette company card

> Integrated Biopharma (INBP) saw revenue fall 19.3% in FY2026 to $44 million, operating margin -6.2% against a -3.8% median for pharmaceutical preparations, equity 69.7% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1016504 · fiscal year ended 2026-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/INBP) · [JSON](https://www.pops4.com/boards/company/INBP.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $44M |
| Revenue growth, 1 year | -19.3% |
| Revenue growth per year | -6.0% |
| Operating margin | -6.2% (prior year 3.7%) |
| Net margin | -6.5% |
| Operating cash flow | $1M |
| Capital spending | $346,000 |
| Free cash flow | $895,000 |
| Cash | $4M |
| Long-term debt | — |
| Total assets | $25M |
| Total equity | $18M |
| Equity ÷ assets | 69.7% |
| Return on equity | -16.1% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: 0.29 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -1.18 (above the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · revenue is hard to predict: its 80% range is ±40%
- Cash Compass: In between · no clear cash pattern yet

## Edgarette's reading

Exposure: revenue $43.9M (FY2026). Experience: revenue down 19.3% on the year, down 6.0% a year over 4 years; operating margin -6.2%, down from 3.7%. Soundness: equity 69.7% of assets, return on equity -16.1%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $24.7M and $57.7M next year (method v4.1: its own 6-year record of growth weighed at 63% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $23.3M to $61.3M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -6.2% against a -3.8% median; growth -19.3% against 13.7%.

Range logged 2026-10-29, receipt 1ecd1e24189de240, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

No warning filings in the window.

## Recent filings

- DEF 14A · filed 2026-10-28 · [filing](https://www.sec.gov/Archives/edgar/data/1016504/000143774926033764/0001437749-26-033764-index.htm)
- 8-K · filed 2026-09-25 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1016504/000143774926031247/0001437749-26-031247-index.htm)
- 10-K · filed 2026-09-25 · [filing](https://www.sec.gov/Archives/edgar/data/1016504/000143774926031241/0001437749-26-031241-index.htm)
- 8-K · filed 2026-08-20 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/1016504/000143774926028628/0001437749-26-028628-index.htm)
- 8-K · filed 2026-07-02 · 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1016504/000143774926022415/0001437749-26-022415-index.htm)
- 8-K · filed 2026-05-08 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1016504/000143774926015928/0001437749-26-015928-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001016504.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1016504

## Cite

POPS4, Edgar & Edgarette: INTEGRATED BIOPHARMA, INC. (INBP) company card, from the company's own SEC filings, accessed 2026-10-29, https://www.pops4.com/boards/company/INBP. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.